



## Berkshire West Area Prescribing Committee Policy Statement

<b>Drug Name</b>	Tiotropium (Braltus Zonda®) inhaler		
<b>Indication under review</b>	Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)		
<b>Policy No:</b>	APC 144		
<b>Date of Issue:</b>	March 2017		
<b>Review Date:</b>	March 2020		
<b>Policy Statement:</b>	Tiotropium Braltus Zonda® inhaler is approved for use in COPD as a first line treatment when tiotropium is indicated.		
<b>Traffic Light Status</b>	<b>Green</b>		
<b>Key Points considered:</b>	<ul style="list-style-type: none"> <li>• The current Berkshire West APC algorithm for the use of inhaled therapies in COPD recommends tiotropium as the first line long acting antimuscarinic agent (LAMA).</li> <li>• The price of Braltus Zonda is significantly lower than the cost of the Spiriva Handihaler representing an opportunity to make large savings to the drugs budget which can be reinvested into the local health economy</li> <li>• Braltus Zonda® is a very similar device to the Spiriva Handihaler with the added advantages of: <ul style="list-style-type: none"> <li>○ Capsules are clear enabling patients to visually confirm that the full dose has been inhaled</li> <li>○ Capsules are packed in a bottle enabling easier retrieval for patients who cannot manage blister packs</li> <li>○ The Zonda inhaler device is similar to the Spiriva Handihaler and operated in a similar way.</li> <li>○ A new Zonda device is dispensed each time without extra cost</li> </ul> </li> <li>• The committee were satisfied that Braltus Zonda is equivalent to the tiotropium handihaler.</li> <li>• Recommendations apply to new and existing patients currently being treated with Spiriva Handihaler.</li> </ul>		
<b>References</b>	Algorta, Jamie et al. Pharmacokinetic Bioequivalence of Two inhaled Tiotropium Bromide Formulations in Healthy Volunteers. Clinical Drug investigation vol 36 (9) pages 753-762 Sept 2016		
<b>Date taken to APC:</b>	1 <sup>st</sup> March 2017		
<b>Date Ratified by GPMOC on Behalf of the Board:</b>	15 <sup>th</sup> March 2017		

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

<b>Brown</b>	<b>Green</b>	<b>Amber</b>	<b>Red</b>
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only